| ORIGINAL ARTICLE |
|
| Year : 2012 | Volume
: 7
| Issue : 3 | Page : 130-134 |
|
|
Study of PTPN22 1858C/T polymorphism in rheumatoid arthritis patients from Western India
Vandana D Pradhan1, Heba Dalvi1, Devraj Parsannavar2, Anjali Rajadhyaksha1, Manisha Patwardhan3, Kanjaksha Ghosh4
1 Department of Clinical & Experimental Immunology, Mumbai, India
2 Scientist National Institute of Nutrition, Hyderabad, India
3 Department of Clinical & Experimental Immunology, fDirector, National Institute of Immunohae- matology, Indian Council of Medical Research, 13th ?oor, Mumbai, India
4 National Institute of Immunohae- matology, Indian Council of Medical Research, 13th ?oor, Mumbai, India
Correspondence Address:
Vandana D Pradhan
Department of Clinical & Experimental Immunology, Mumbai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.1016/j.injr.2012.06.003
|
|
|
Background: Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder with etiologies including genetic and environmental factors. Protein tyrosine phosphatase non-receptor type22 (PTPN22) 1858C/T polymorphism is widely suspected to be a susceptibility gene for RA in the non-HLA genes group.
Aim: This study aimed at determining whether PTPN22 1858C/T polymorphism is associated with RA patients from Western India and to evaluate its possible association with rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies.
Methods: A total of 130 Indian RA patients and 100 age and sex matched normal controls were genotyped by polymerase chain reaction restriction fragment length polymorphism (PCReRFLP) for the PTPN22 1858C/T polymorphism.
Results: RF positivity was seen among 73.8% RA patients studied and the overall incidence of anti-CCP antibodies was 86.2%. The homozygous genotype (T/T) was absent in both groups. Among RF positives, C/C homozygosity was 90.6% whereas 9.4% patients were C/T heterozygous. Among anti-CCP positives, 89.1% had C/C genotype while the remaining 10.9% have the C/T genotype. Statistically significant association was obtained between the polymorphism and anti-CCP positivity in RA patients (OR: 2.939, 'p' value Ό 0.0595).
Conclusion: Our study suggested that a positive autoantibody status may predispose an individual to RA. PTPN22
may act as a susceptibility gene only in certain ethnic groups and there is no direct association between PTPN22 C1858 polymorphism and RA patients from Western India. Still a larger study is needed to understand whether this polymorphism predisposes individual to disease-associated antibodies among Indian RA patients.
|
|
|
|
| [PDF]* |
|
 |
|
